NEWAMSTERDAM PHARMA COMPANY N.V.

Analyst Reco. NewAmsterdam Pharma Company N.V. Deutsche Boerse AG

Equities

KH6

NL00150012L7

Market Closed - Deutsche Boerse AG Other stock markets 09:29:01 2024-06-28 EDT			5-day change	1st Jan Change
17.4 ^EUR	-0.57%		+13.73%	+77.55%

06-11	NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043	MT
06-10	Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

TD Cowen Starts NewAmsterdam Pharma With Buy Rating	05-15	MT
Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target	03-14	MT
RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk	02-29	MT
Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target	01-18	MT
RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target	23-10-30	MT
Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating	23-04-03	MT
Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target	23-01-06	MT
SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target	22-12-20	MT
SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target	22-12-20	MT
William Blair Starts NewAmsterdam Pharma at Outperform	22-12-19	MT
Jefferies Starts NewAmsterdam Pharma at Buy With $24 Price Target	22-12-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer